Is there a need to take ethnicity into account when considering lung cancer treatment?

References

• Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J. Clin. Oncol.24, 2137–2150 (2006).
   PubMed Web of Science ®Google Scholar
• Haiman CA, Stram DO, Wilkens LR et al. Ethnic and racial differences in the smoking-related risk of lung cancer. N. Engl. J. Med.354, 333–342 (2006).
   PubMed Web of Science ®Google Scholar
• DiMasi JA, Grabowski HG. Economics of new oncology drug development. J. Clin. Oncol.25, 209–216 (2007).
   PubMed Web of Science ®Google Scholar
• Sekine I, Nokihara H, Yamamoto N et al. Common arm analysis: one approach to develop the basis for global standardization in clinical trials of non-small cell lung cancer. Lung Cancer53, 157–164 (2006).
   PubMed Web of Science ®Google Scholar
• Lara P, Redman M, Lenz H et al. Cisplatin (Cis)/etoposide (VP16) compared to cis/irinotecan (CPT11) in extensive-stage small cell lung cancer (E-SCLC): pharmacogenomic (PG) and comparative toxicity analysis of JCOG 9511 and SWOG 0124. J. Clin. Oncol.25(Suppl.), 390S (2007) (Abstract 7524).
   PubMed Web of Science ®Google Scholar
• O’Dwyer PJ, Catalano RB. Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy. J. Clin. Oncol.24, 4534–4538 (2006).
   PubMed Web of Science ®Google Scholar
• Sai K, Saito Y, Sakamoto H et al. Importance of UDP-glucuronosyltransferase 1A1*6 for irinotecan toxicities in Japanese cancer patients. Cancer Lett.261, 165–171 (2008).
   PubMed Web of Science ®Google Scholar
• Minami H, Sai K, Saeki M et al. Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. Pharmacogenet. Genomics17, 497–504 (2007).
   PubMed Web of Science ®Google Scholar
• Kaniwa N, Kurose K, Jinno H et al. Racial variability in haplotype frequencies of UGT1A1 and glucuronidation activity of a novel single nucleotide polymorphism 686C>T (P229L) found in an African–American. Drug Metab. Dispos.33, 458–465 (2005).
   PubMed Web of Science ®Google Scholar
• Saeki M, Saito Y, Jinno H et al. Haplotype structures of the UGT1A gene complex in a Japanese population. Pharmacogenomics J.6, 63–75 (2006).
   PubMed Web of Science ®Google Scholar
• Bosch TM, Huitema AD, Doodeman VD et al. Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel. Clin. Cancer Res.12, 5786–5793 (2006).
   PubMed Web of Science ®Google Scholar
• Soo RA, Wang LZ, Ng SS et al. Distribution of gemcitabine pathway genotypes in ethnic Asians and their association with outcome in non-small cell lung cancer patients. Lung Cancer63(1), 121–127 (2009).
   PubMed Web of Science ®Google Scholar
• Fukuoka M, Yano S, Giaccone G et al. Multi-institutional randomized Phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 trial) [corrected]. J. Clin. Oncol.21, 2237–2246 (2003).
   PubMed Web of Science ®Google Scholar
• Kris MG, Natale RB, Herbst RS et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA290, 2149–2158 (2003).
   PubMed Web of Science ®Google Scholar
• Thatcher N, Chang A, Parikh P et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet366, 1527–1537 (2005).
   PubMed Web of Science ®Google Scholar
• Tamura T, Nishiwaki Y, Watanabe K et al. Evaluation of efficacy and safety of erlotinib as monotherapy for Japanese patients with advanced non-small cell lung cancer (NSCLC); integrated analysis of two Japanese Phase II studies. J. Thorac. Oncol.2(Suppl.), S742 (2007).
   Google Scholar
• Perez-Soler R, Chachoua A, Hammond LA et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J. Clin. Oncol.22, 3238–3247 (2004).
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med.353, 123–132 (2005).
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med.350, 2129–2139 (2004).
   PubMed Web of Science ®Google Scholar
• Paez JG, Janne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science304, 1497–1500 (2004).
   PubMed Web of Science ®Google Scholar
• Yamamoto H, Toyooka S, Mitsudomi T. Impact of EGFR mutation analysis in non-small cell lung cancer. Lung Cancer DOI: doi:10.1016/j.lungcan.2008.06.021 (2008) (Epub ahead of print).
   Google Scholar
• Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res.54, 4855–4878 (1994).
   PubMed Web of Science ®Google Scholar
• Matsuo K, Ito H, Yatabe Y et al. Risk factors differ for non-small-cell lung cancers with and without EGFR mutation: assessment of smoking and sex by a case–control study in Japanese. Cancer Sci.98, 96–101 (2007).
   PubMedGoogle Scholar
• Toyooka S, Matsuo K, Shigematsu H et al. The impact of sex and smoking status on the mutational spectrum of epidermal growth factor receptor gene in non small cell lung cancer. Clin. Cancer Res.13, 5763–5768 (2007).
   PubMedGoogle Scholar
• Liu W, Innocenti F, Chen P et al. Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism. Clin. Cancer Res.9, 1009–1012 (2003).
   PubMed Web of Science ®Google Scholar
• Matsuo K, Hiraki A, Ito H et al. Soy consumption reduces the risk of non-small-cell lung cancers with epidermal growth factor receptor mutations among Japanese. Cancer Sci.99, 1202–1208 (2008).
   PubMed Web of Science ®Google Scholar
• Bell DW, Brannigan BW, Matsuo K et al. Increased prevalence of EGFR-mutant lung cancer in women and in East Asian populations: analysis of estrogen-related polymorphisms. Clin. Cancer Res.14, 4079–4084 (2008).
   PubMedGoogle Scholar
• Herbst RS, Giaccone G, Schiller JH et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a Phase III trial – INTACT 2. J. Clin. Oncol.22, 785–794 (2004).
   PubMed Web of Science ®Google Scholar
• Giaccone G, Herbst RS, Manegold C et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a Phase III trial – INTACT 1. J. Clin. Oncol.22, 777–784 (2004).
   PubMed Web of Science ®Google Scholar
• Mok T, Wu Y-L, Thongprasert S et al. Phase III, randomised, open-label, first-line study of gefitinib (G) vs carboplatin/paclitaxel (C/P) in clinically selected patients (pts) with advanced non-small-cell lung cancer (NSCLC) (IPASS). Presented at: The 33rd European Society of Medical Oncology Congress, Stockholm, 12–16 September 2008.
   Google Scholar